NEXTGEN BIOLOGICS Trademark

Trademark Overview

On Tuesday, September 13, 2016, a trademark application was filed for NEXTGEN BIOLOGICS with the United States Patent and Trademark Office. The USPTO has given the NEXTGEN BIOLOGICS trademark a serial number of 87169772. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 26, 2022. This trademark is owned by Moderna Therapeutics, Inc.. The NEXTGEN BIOLOGICS trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Medical, biological, and pharmaceutical preparations for the treatment of cancer, prevention and treatment of infectious diseases, treatment of genetic diseases; RNA-based therapeutic agents for producing and delivering therapeutic and antigenic proteins; medical diagnostic reagents

Biochemical catalysts, reagents, diagnostic reagents, and assays all for research use; chemicals for use in the manufacture or product development of biotherapeutics, biosimilars, pharmaceuticals, and therapeutics; nucleic acid products and reagents for laboratory use

Scientific research and development in the fields of pharmaceuticals, medicine, biologics, biotherapeutics, biosimilars and therapeutics
nextgen biologics

General Information

Serial Number87169772
Word MarkNEXTGEN BIOLOGICS
Filing DateTuesday, September 13, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 26, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 24, 2019

Trademark Statements

Goods and ServicesMedical, biological, and pharmaceutical preparations for the treatment of cancer, prevention and treatment of infectious diseases, treatment of genetic diseases; RNA-based therapeutic agents for producing and delivering therapeutic and antigenic proteins; medical diagnostic reagents
Pseudo MarkNEXT GEN BIOLOGICS
Goods and ServicesBiochemical catalysts, reagents, diagnostic reagents, and assays all for research use; chemicals for use in the manufacture or product development of biotherapeutics, biosimilars, pharmaceuticals, and therapeutics; nucleic acid products and reagents for laboratory use
Disclaimer with Predetermined Text"BIOLOGICS"
Goods and ServicesScientific research and development in the fields of pharmaceuticals, medicine, biologics, biotherapeutics, biosimilars and therapeutics

Classification Information

International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateFriday, September 16, 2016
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 16, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 16, 2016
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMODERNATX, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCAMBRIDGE, MA 02139
Party NameMODERNATX, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressCAMBRIDGE, MA 02139
Party NameModerna Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MI 02141

Trademark Events

Event DateEvent Description
Tuesday, December 27, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 26, 2022ABANDONMENT - NO USE STATEMENT FILED
Thursday, April 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 27, 2022SOU EXTENSION 5 GRANTED
Friday, April 22, 2022SOU EXTENSION 5 FILED
Wednesday, April 27, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, April 22, 2022SOU TEAS EXTENSION RECEIVED
Thursday, November 11, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 9, 2021SOU EXTENSION 4 GRANTED
Tuesday, November 9, 2021SOU EXTENSION 4 FILED
Tuesday, November 9, 2021SOU TEAS EXTENSION RECEIVED
Thursday, April 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 13, 2021SOU EXTENSION 3 GRANTED
Tuesday, April 13, 2021SOU EXTENSION 3 FILED
Tuesday, April 13, 2021SOU TEAS EXTENSION RECEIVED
Friday, November 20, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 18, 2020SOU EXTENSION 2 GRANTED
Wednesday, November 18, 2020SOU EXTENSION 2 FILED
Wednesday, November 18, 2020SOU TEAS EXTENSION RECEIVED
Saturday, April 18, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 16, 2020SOU EXTENSION 1 GRANTED
Thursday, April 16, 2020SOU EXTENSION 1 FILED
Thursday, April 16, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, November 19, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 24, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 24, 2019PUBLISHED FOR OPPOSITION
Wednesday, September 4, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, August 21, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 20, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, August 15, 2019TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, July 31, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 31, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 31, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 23, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 23, 2019NON-FINAL ACTION E-MAILED
Tuesday, April 23, 2019NON-FINAL ACTION WRITTEN
Wednesday, March 27, 2019SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Wednesday, September 26, 2018REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, June 29, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, June 29, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, May 23, 2018ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, May 23, 2018TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, March 26, 2018REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, March 26, 2018ASSIGNED TO LIE
Monday, September 11, 2017REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, March 9, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, March 9, 2017LETTER OF SUSPENSION E-MAILED
Thursday, March 9, 2017SUSPENSION LETTER WRITTEN
Wednesday, March 8, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 7, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 7, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, December 13, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, December 13, 2016NON-FINAL ACTION E-MAILED
Tuesday, December 13, 2016NON-FINAL ACTION WRITTEN
Tuesday, December 6, 2016ASSIGNED TO EXAMINER
Wednesday, November 2, 2016AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Saturday, September 17, 2016NOTICE OF PSEUDO MARK E-MAILED
Friday, September 16, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, September 16, 2016NEW APPLICATION ENTERED

Related Keywords

biologics nextgen reagents treatment biotherapeutics biosimilars pharmaceuticals development diagnostic research therapeutics medical